Annual report
4886.TEDINET S100YEAY
Period2025-04-01 → 2026-03-31
Filed2026-06-19
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥71.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥64.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥62.8bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥60.5bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥5.8bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥5.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥5.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥6.5bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.2bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥7.0bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥6.2bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.4bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥7.5bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.2bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.6bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥112.4bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥104.3bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥90.7bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥87.1bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥83.3bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥35.6bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥32.5bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥76.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥71.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥61.9bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥54.5bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥48.9bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥10.1bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥10.1bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.5bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥17.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.5bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥5.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥818m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.9bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.8bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥191.12 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.95 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥266.51 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.08 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,477.81 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,302.61 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,186.1 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,928.14 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,734.8 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 62.6% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.3% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 8.0% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.0% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.8% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,611 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,632 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 762 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 747 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 777 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥4.4bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥4.5bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.7bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥1.7bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥1.4bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.5bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥603m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥717m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.4bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.4bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥2.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥591m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥682m | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥52.4bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥48.3bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥43.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥41.6bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥41.3bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.9bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.6bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥45.5bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥44.6bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.7bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥40.9bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥40.7bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.1bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.4bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥83.99 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.57 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.1 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥20.95 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥23.79 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥60 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥55 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,602.01 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,574.11 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,506.47 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,447.55 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,443.94 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 86.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.5% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.7% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 98.5% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 5.3% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.7% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 28,763,199 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 28,763,199 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 30,563,199 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 94 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 80 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 75 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 79 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 74 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 63
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 17 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥306m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥225m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥81m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2026-03-31 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | −¥13m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥246m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥81m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥81m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥42.3bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.7bn |
| Animal Health Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥3m |
| Animal Health Businessreportable segment | employees | at 2026-03-31 | 30 pure |
| Animal Health Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Animal Health Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥7.3bn |
| Animal Health Businessreportable segment | segment assets | at 2026-03-31 | ¥3.9bn |
| Animal Health Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥344m |
| Oversea Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥340m |
| Oversea Businessreportable segment | employees | at 2026-03-31 | 845 pure |
| Oversea Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| Oversea Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥4.6bn |
| Oversea Businessreportable segment | segment assets | at 2026-03-31 | ¥17.0bn |
| Oversea Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥108m |
| Pharmaceutical Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥2.0bn |
| Pharmaceutical Businessreportable segment | employees | at 2026-03-31 | 629 pure |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥58.9bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥58.9bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2026-03-31 | ¥49.1bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥7.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥2.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥71.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥71.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥81m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥70.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥7.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥325m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥237m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥88m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥51m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥192m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥88m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥88m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥31.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥1.3bn |
| Animal Health Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥3m |
| Animal Health Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥7.2bn |
| Animal Health Businessreportable segment | segment assets | at 2025-03-31 | ¥4.2bn |
| Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥300m |
| Oversea Businessreportable segment | segment assets | at 2025-03-31 | ¥18.6bn |
| Pharmaceutical Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥56.7bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥56.7bn |
| Pharmaceutical Businessreportable segment | segment assets | at 2025-03-31 | ¥49.6bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥64.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥64.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥88m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥72.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥6.7bn |
| Oversea Businessreportable segment | employees | at 2026-03-31 | 11 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,703
| Item | Context | Value | Unit |
|---|---|---|---|
| Company name cover page | FilingDateInstant | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | ASKA Pharmaceutical Holdings Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山口 惣大 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝浦二丁目５番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)（03）5484－8845（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)グループ経理部長 畠山 智之 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝浦二丁目５番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)（03）5484－8845（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)グループ経理部長 畠山 智之 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35791 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 48860 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | ASKA Pharmaceutical Holdings Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2025-04-01 | |
| Current period end date | FilingDateInstant | 2026-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2026-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Comparative period end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Business policy business environment issues to address etc (text) | FilingDateInstant | Text · Plus | |
| Disclosure of sustainability related financial information (text) | FilingDateInstant | Text · Plus | |
| Governance (text) | FilingDateInstant | Text · Plus | |
| Risk management (text) | FilingDateInstant | Text · Plus | |
| Governance climate change (text) | FilingDateInstant | Text · Plus | |
| Reference to other information governance climate change | FilingDateInstant | Original text (Japanese)①ガバナンス | |
| Strategy climate change (text) | FilingDateInstant | Text · Plus | |
| Risk management climate change (text) | FilingDateInstant | Text · Plus | |
| Reference to other information risk management climate change | FilingDateInstant | Original text (Japanese)②リスク管理 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |